

Supplementary Table 2. CAR-T related toxicities. Characteristics of the CAR-T related toxicities at their onset of the patients with “Tox-onset” and “Post-IMT” samples.

	N (%) (n= 19)
CRS	19 (100)
Grade	
Grade 1	3 (15.8)
Grade 1 persistent	6 (31.6)
Grade 2	7 (36.8)
Grade 3	2 (10.5)
Grade 4	1 (5.3)
Clinical features	
Hypotension	6 (31.6)
Need for vasopressors	2 (10.5)
Hypoxemia	7 (36.8)
Need for FiO ₂ >40%	1 (5.3)
Treatment	
Immunomodulatory treatment for CRS (yes)	16 (84.2)
Tocilizumab	16 (84.2)
Doses of tocilizumab (median± IQR)	1.5 ± 1
Refractoriness to tocilizumab (yes)	3 (15.8)
Siltuximab	1 (5.3)
Corticosteroids	2 (10.5)
ICANS	8 (42.1)
Grade	
Grade 1	2 (10.5)
Grade 2	2 (10.5)
Grade 3	1 (5.3)
Grade 4	3 (15.8)
Treatment	
Immunomodulatory treatment for ICANS (yes)	8 (42.1)
Corticosteroids	8 (42.1)
Duration corticosteroids (days, median± IQR)	22 ± 37.2
Refractoriness to corticosteroids	1 (5.3)
Siltuximab	1 (5.3)
Anakinra	1 (5.3)

Tox-onset: Sample at the onset of the toxicity. Post-IMT: sample within the first 24-48h after the immunomodulatory treatment. IMT: immunomodulatory treatment. CRS: cytokine release syndrome; ICANS: Immune effector cell-associated neurotoxicity syndrome; FiO₂: fraction of inspired oxygen; IQR: interquartile range.